Impact on Optical Coherence Tomographic Coronary Findings of Fluvastatin Alone Versus Fluvastatin + Ezetimibe

Habara, Maoto; Nasu, Kenya; Terashima, Mitsuyasu; Ko, Euihong; Yokota, Daisuke; Ito, Tetsuhide; Kurita, Tairo; Teramoto, Tamio; Kimura, Masashi; Kinoshita, Yoshihisa; Tsuchikane, Etsuo; Asakura, Yasushi; Matsubara, Takehiro; Suzuki, Takahiko

doi:10.1016/j.amjcard.2013.10.038

Cited by 53 publications

(40 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…regard to the lipid-lowering effects of a statin/ezetimibe combination, even in the present PRECISE-IVUS trial, the dual lipid-lowering strategy was associated with lower LDL-C levels at follow-up and greater reduction in LDL-C during the study compared with statin monotherapy, which is similar to previous studies(6,19). Our results reaffirmed the relationship between the achieved lower LDL-C level and coronary plaque regression.…”

supporting

confidence: 95%

Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention

Tsujita

Sugiyama²,

Sumida

et al. 2015

Journal of the American College of Cardiology

345

114

View full text Add to dashboard Cite

show abstract

supporting

confidence: 95%

Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention

Tsujita

Sugiyama²,

Sumida

et al. 2015

Journal of the American College of Cardiology

345

114

View full text Add to dashboard Cite

show abstract

“…Habara, et al reported that combination therapy with ezetimibe and fluvastatin increased the fibrous cap thickness of lipid-rich coronary plaque compared with fluvastatin alone in patients with stable CAD. 25) Bogiatzt, et al reported in their observational study that the addition of ezetimibe to ongoing statin administration produced significant regression of carotid plaque burden. 26) Comparison with previous IVUS studies: The present reduction in atheroma volume was considerably larger than those previously reported in Western populations, such as in AS-TEROID and REVERSAL.…”

Section: Discussionmentioning

confidence: 99%

Effect of Combination Therapy of Ezetimibe and Rosuvastatin on Regression of Coronary Atherosclerosis in Patients With Coronary Artery Disease

et al. 2015

View full text Add to dashboard Cite

SummaryEzetimibe has been reported to provide significant incremental reduction in low-density-lipoprotein cholesterol (LDL-C) when added to a statin; however, its effect on coronary atherosclerosis has not yet been evaluated in detail. The aim of this study was to investigate the add-on effect of ezetimibe to a statin on coronary atherosclerosis evaluated by intravascular ultrasound (IVUS).In this prospective randomized open-label study, a total of 51 patients with stable coronary artery disease (CAD) requiring percutaneous coronary intervention (PCI) were enrolled, and assigned to a combination group (n = 26, rosuvastatin 5 mg/day + ezetimibe 10 mg/day) or a monotherapy group (n = 25, rosuvastatin 5 mg/day). Volumetric IVUS analyses were performed at baseline and 6 months after the treatment for a non-PCI site. LDL-C level was significantly reduced in the combination group (-55.8%) versus that in the monotherapy group (-36.8%; P = 0.004). The percent change in plaque volume (PV), the primary endpoint, appeared to decrease more effectively in the combination group compared with the monotherapy group (-13.2% versus -3.1%, respectively, P = 0.050). Moreover, there was a significant group × time interaction in the effects of the two treatments on PV (P = 0.021), indicating the regressive effect of the combination therapy on PV was greater than that of monotherapy for subtly different values of baseline PV in the two treatment groups. Moreover, percent change in PV showed positive correlations with percent change of LDL-C (r = 0.384, P = 0.015).Intensive lipid-lowering therapy with ezetimibe added to usual-dose statin may provide significant incremental reduction in coronary plaques compared with usual-dose statin monotherapy. (Int Heart J 2015; 56: 278-285)

show abstract

“…The LDL-C level could be reduced by an additional 23% to 24% by the addition of ezetimibe to statins (46)(47)(48). With regard to its effect on plaque composition, it has been shown that ezetimibe, when added to fluvastatin, increased the fibrous cap thickness and reduced lipid plaque (49).…”

Section: Reduction Of Ldl Cholesterol and Modification Of Plaque Instmentioning

confidence: 90%

Stabilization of high-risk plaques

Takata¹,

Imaizumi²,

Zhang³

et al. 2016

Cardiovasc. Diagn. Ther.

View full text Add to dashboard Cite

Impact on Optical Coherence Tomographic Coronary Findings of Fluvastatin Alone Versus Fluvastatin + Ezetimibe

Cited by 53 publications

References 17 publications

Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention

Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention

Effect of Combination Therapy of Ezetimibe and Rosuvastatin on Regression of Coronary Atherosclerosis in Patients With Coronary Artery Disease

Stabilization of high-risk plaques

Contact Info

Product

Resources

About